Haleon entered into an agreement to fully acquire Chinese joint venture Tianjin TSKF Pharmaceuticals in a deal valued at 200 million pounds ($263.8 million), lifting its stake to 100% from 88% ...

As a hybrid healthcare and consumer staple stock, Haleon offers plenty of stability amidst the current market volatility, with its Power Brands driving strong organic growth. Room for expanding ...

(Sharecast News) - Haleon announced on Tuesday that it has agreed to acquire the remaining 12% stake in its Chinese over-the-counter joint venture, Tianjin TSKF Pharmaceutical, for CNY 1.623bn ...

Pfizer sold its remaining 7.3% stake in Haleon for $3.1 billion, fully exiting its position in the company. Haleon expects 2025 organic revenue growth of 4% to 6%, with stronger performance in the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Pfizer (NYSE:PFE) has generated £2.5B ($3.24B) after selling its entire stake in Haleon (NYSE:HLN), the consumer healthcare company it established with the British pharmaceutical giant GSK (GSK ...

Haleon is to axe diversity targets from its executive bonus scheme in the latest sign that UK businesses are rowing back on DEI. The Sensodyne-maker has confirmed that its chief executive and ...

Pfizer sold its entire 7.3% shareholding in London-listed consumer-health company Haleon for a net sum of 2.5 billion pounds ($3.25 billion). Pfizer sold 618 million shares for 385 pence each.

Pfizer PFE has sold off its remaining stake in consumer health company Haleon HLN to institutional investors and Haleon itself for around $3.3 billion. Pfizer sold its 7.3% stake in Haleon ...